威高血净上半年净利润2.2亿元，同比增长10.11%

Core Viewpoint - Weigao Blood Products (603014.SH) reported a positive financial performance in the first half of 2025, indicating growth in both revenue and net profit [1] Financial Performance - The company achieved a total operating revenue of 1.765 billion yuan, representing a year-on-year increase of 8.52% [1] - The net profit attributable to shareholders reached 220 million yuan, reflecting a year-on-year growth of 10.11% [1] - Basic earnings per share were reported at 0.58 yuan [1] Dividend Distribution - The company proposed a cash dividend of 1.6 yuan (including tax) for every 10 shares to all shareholders [1]